The discrepancy between scientific advances in psychiatry and the reality of treatment of psychoses

Neurology Psychiatry and Brain Research

Volumn 11, Issue 4, 2004, Pages 165-170

  Gross, Gisela ^a   Huber, Gerd ^a,b  

^a Universitäts Nervenklinik ^*

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Changing to the worse of the treatment of psychiatric patients despite of the advances of psychopharmacological and neuroscience based psychiatric research; Conventional and new generation antipsychotics; Trend towards a two classes psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

CLINICAL TRIAL; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HOSPITAL CARE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MEDICAL RESEARCH; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; NEUROSCIENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RESOURCE ALLOCATION; REVIEW; RISK; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 14644423314     PISSN: 09419500     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Chakos M, Lieberman J et al (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 158:518-526.
2. Gaebel W, Riesbeck M et al (2003) Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Eur Arch Psychiatry Clin Neurosci 253:175-184.
3. Geddes J, Freemantle N et al (2000) Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and metaregression analysis. BMJ 321:1371-1376.
4. Gross G, Huber G (1998) Prodromes and primary prevention of schizophrenic psychoses. Neurol Psychiatry Brain Res 6:51-58.
5. Gross G, Huber G, Klosterkötter J (1992) Early diagnosis of schizophrenia. Neurol Psychiatry Brain Res 1:17-22.
6. Gross G, Huber G, Klosterkötter J (1998) The early phase of schizophrenia and prediction of outcome. Int Clin Psychopharmacol 13(S1):13-21.
7. Hamann J, Pfeiffer H et al (2002) Gibt es Defizite in der Verordnung atypischer Antipsychotika für schizophrene Patienten? Nervenarzt 73(S1):185-186.
8. Huber G (1995) Prodrome der Schizophrenie. Fortschr Neurol Psychiat 63:131-138.
9. Huber G (2002) Advances in the treatment of schizophrenic and related disorders. Neurol Croat 51(S1):14-21.
10. Huber G (2004) Psychiatrie. 7th edition. Schattauer, Stuttgart.
11. Huber G, Gross G (1997) Advances in therapy and prevention of schizophrenic disorders. Neurol Psychiatry Brain Res 5:1-8.
12. Huber G, Gross G (1999) Conventional and newer neuroleptics in the treatment of schizophrenia spectrum disorders. Neurol Psychiatry Brain Res 7:15-26.
13. Leucht S, Pitschel-Walz G et al (1999) Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schi Res 35:51-68.
14. Leucht S, Barnes TR et al (2003) Relapse prevention in schizophrenia with new generation antipsychotics: A systematic review and exploratory meta-analysis of randomized controlled trials. Am J Psychiatry 15:23-31.
15. Licinio J (2004) A leadership crisis in American psychiatry. Mol Psychiatry 9:1.
16. Roth-Sackenheim C (2003) Qualifizierte Behandlung nur noch Utopie? Neurotransmitter 12:42-48.
17. Thomas D (2000) Medicine's least respectable branch? Nature 403:19-20.